Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care.

J Manag Care Pharm. 2008 Nov-Dec;14(9):870-7

Authors: Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Faresjo T, Timpka T

BACKGROUND: Irritable bowel syndrome (IBS) has an estimated 10%-12% prevalence in industrial countries. Studies from the United States have shown that IBS causes notable financial losses for employers. Due to the lack of pathophysiological markers, only a fraction of the pharmacological management of IBS has focused on etiological mechanisms. We hypothesized that there is a high consumption of nonspecific drugs among patients with IBS in their attempts to manage symptoms.

Clinical significance of Neutrophil gelatinase-associated lipocalin(NGAL) expression in primary rectal cancer.

BMC Cancer. 2009;9:134

Authors: Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, Wang OC, Guo GL, Yang GY, Hu XQ BACKGROUND: Emerging evidence has demonstrated that Neutrophil gelatinase-associated lipocalin (NGAL) is up-regulated in multiple malignancies, including oesophagus cancer, and plays a critical role in tumorigenesis and progression. However, till now, little is known about the role of NGAL in human rectal cancer. Its association with clinicopathologic characteristics and expression of MMP-9, one of its target genes, has not been reported systematically in rectal cancer.